Filtered By:
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 342 results found since Jan 2013.
The relationship between eosinophils and reduction in major adverse cardiac events in ETHOS
Conclusion: Overall, there were fewer MACE in ICS-containing therapy groups than GFF. While event numbers were low, benefits of BGF vs GFF on CV death and non-fatal MI related to higher baseline EOS were consistent with the reduction in ACM with increasing EOS previously observed (Martinez, F.J. et al. Am J Respir Crit Care Med 2020. Epub ahead of print).
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Bafadhel, M., Rabe, K. F., Singh, D., Jenkins, M., Dorinsky, P., Patel, M. Tags: Airway pharmacology and treatment Source Type: research
A case of inflammatory cerebral amyloid angiopathy after ischemic stroke - a potential risk factor related to blood-brain barrier disruption
We present a patient with history of CAA who developed probable CAA-ri/ABRA three months after an acute ischemic stroke.
Source: Clinical Imaging - November 19, 2021 Category: Radiology Authors: Dora Chen, Michelle Roytman, Kyriakos A. Kirou, Babak B. Navi, Andrew D. Schweitzer Tags: Neuroradiology Source Type: research
A historical cohort study to investigation of statins safety in COVID-19 hospitalized patients
CONCLUSION: The use of statins did not seem to change outcomes in COVID19.PMID:34776254 | DOI:10.1016/j.therap.2021.10.006
Source: Therapie - November 15, 2021 Category: Psychiatry & Psychology Authors: Saeed Nateghi Mohammad Mahmoudi Gomari Hadiseh Hosamirudsari Behnam Behnoush Asma Razmjoofard Goli Azimi Shokooh Ordookhani Ali Jafarpour Neda Faraji Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Susac syndrome complicating a SARS-CoV-2 infection
We present a case of a 40-year-old man diagnosed with Susac syndrome after COVID-19, presenting with acute sensorineural hearing loss, encephalopathy, a splenial “snowball-like” lesion, and branch retinal artery occlusions with distal arterial wall hyperintensity. Although the pathophysiology of Susac syndrome remains unclear, this case is in line with the ongoing debate about the influence of SARS-CoV-2 on the human immune system. Corticosteroid treatme nt was initiated, followed by two treatments with rituximab, with clinical improvement of the symptomatology. Maintenance treatment currently consists of mycophenolic ...
Source: Journal of NeuroVirology - November 4, 2021 Category: Neurology Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Comparison of the effectiveness of pulsed radiofrequency of the suprascapular nerve and intra-articular corticosteroid injection for hemiplegic shoulder pain management
J Integr Neurosci. 2021 Sep 30;20(3):687-693. doi: 10.31083/j.jin2003073.ABSTRACTMany patients complain of hemiplegic shoulder pain following stroke. Here, the effectiveness of pulsed radiofrequency stimulation of the suprascapular nerve is compared with intra-articular corticosteroid injection for chronic hemiplegic shoulder pain following stroke. This single-center, prospective, randomized controlled study included 20 patients with hemiplegic shoulder pain after stroke, randomly assigned to the pulsed radiofrequency and intra-articular corticosteroid injection treatment groups (n = 10 in each). Hemiplegic shoulder pain s...
Source: Journal of Integrative Neuroscience - October 14, 2021 Category: Neuroscience Authors: Tae Hoon Kim Min Cheol Chang Source Type: research
